Chrysalis BioTherapeutics, Inc.

GALVESTON, TX · Biotech · Private

TP508 (rusalatide acetate), a regenerative peptide therapeutic that restores endothelial function and activates stem cells to mitigate acute radiation syndrome

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: GALVESTON, TX
Latest Form D: $515K, Mar 2024
Total capital: $27.2M

Federal grants: $5M; 3 awards · 2016–2018; Rank in peer group#166 of 514
Private capital raised: $515K; 1 Form D · last Mar 2024; 31 months since last filing
Federal contracts: $21.7M; 4 awards · Health and Human S; Rank in Biotech#40 of 4373
Granted patents: 0; 2 pending

Capital timeline

Latest events

Mar 2024Private capital raisedForm D · SEC · 1st filing$515K
Jul 2019Federal contractHealth and Human S · Demonstrate Large Animal Efficacy, Define Protocols For The Pivotal Animal Trial, And Better Understand The Pharmacodynamics Of TP508. To Achieve This Objective, We Will Conduct Non-clinical Efficacy Survival Studies In Male And Female Minipigs With$13M
Mar 2018Federal grantHealth and Human S · Phase II · TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure$1M
Mar 2017Federal grantHealth and Human S · Phase II · TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure$1M
Jan 2017Federal contractHealth and Human S · Igf::ot::igf TP508: A Novel Nuclear Countermeasure Targeting Endothelial Cells And Stem Cellsto Combat Ars And Delayed Multiple Organ Dysfunction$7M
Apr 2016Federal grantHealth and Human S · Phase II · TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure$3M
Sep 2013Federal contractHealth and Human S · Igf::ot::igf TP508 Mitigates Radiotherapy-induced Tissue Damage - Period Of Performance 9/20/2013 - 9/19/2015$1.5M

Show 1 earlier federal award

Sep 2011Federal contractHealth and Human S · TAS::75 0849::TAS$200K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

150months

from Chrysalis BioTherapeutics, Inc.’s first federal award to its first private round.

First federal award · Sep 2011: Health and Human S · $200K
First Form D · Mar 2024: $515K · 1st Form D
Awards before first raise: 7 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#166 · top 32%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Darrell CarneyExecutive Officer, DirectorNamed in SEC Form D filings
James RyabyDirectorNamed in SEC Form D filings
Jeffery SheldonDirectorNamed in SEC Form D filings
Lauri SowerExecutive OfficerNamed in SEC Form D filings
Marie RobbDirectorNamed in SEC Form D filings
Timothy SchmidtDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 2

PendingTP508 MrnasUSPTOApplication 63456601
PendingTP508 Acute Therapy For Patients With Severe SARS-COV-2 InfectionUSPTOApplication 63006492

MICROBIOTIX, INC.Similar federal contract value in Biotech · $23.7M in contracts
Biospyder Technologies, Inc.Similar federal contract value in Biotech · $23.1M in contracts
HUMANETICS CORPSimilar federal contract value in Biotech · $22M in contracts
Mammoth BiosciencesSimilar federal contract value in Biotech · $20.8M in contracts
Oxford Nanopore TechnologiesSimilar federal contract value in Biotech · $19.9M in contracts
Rxbio, Inc.Similar federal contract value in Biotech · $18.8M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.